SEC Comment Letter for Silexion Therapeutics Corp (SLXN, SLXNW) (CIK 0002022416) (SLXN) — Jun 15, 2026
Silexion Therapeutics Corp (SLXN, SLXNW) (CIK 0002022416)
Date: June 15, 2026 · CIK: 0002022416 · Accession: 0000000000-26-005985
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296739
Letter
Re: Silexion Therapeutics Corp Registration Statement on Form S-3 Filed June 12, 2026 File No. 333-296739 Dear Ilan Hadar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions.
June 15, 2026
Ilan Hadar Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 15, 2026 Ilan Hadar Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Re: Silexion Therapeutics Corp Registration Statement on Form S-3 Filed June 12, 2026 File No. 333-296739 Dear Ilan Hadar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel </TEXT> </DOCUMENT>